10-Q: Fennec Pharmaceuticals Reports Strong Q2 2026 Results

Fennec Pharmaceuticals Inc. announced robust second quarter 2026 financial results, driven by a 78% year-over-year increase in PEDMARK net product sales and a significant improvement in Adjusted EBITDA.

Summary

• Fennec Pharmaceuticals Inc. reported strong financial results for the second quarter ended June 30, 2026.
• Net product sales of PEDMARK reached $17.1 million, a 78% increase compared to $9.7 million in the second quarter of 2025.
• Total revenue for the quarter was $17.9 million, up from $9.7 million in the prior year period.
• The company achieved a net income of $2.0 million ($0.06 per basic share) for the quarter, a significant improvement from a net loss of $3.2 million ($0.11 per basic share) in Q2 2025.
• Non-GAAP Adjusted EBITDA was $2.8 million for the quarter, a substantial increase from a loss of $1.2 million in the prior year period.
• Cash and cash equivalents increased to $41.2 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and a significant improvement in profitability and cash flow from operations, indicating effective commercialization of PEDMARK.

Positives

• Significant year-over-year revenue growth for PEDMARK, with net sales increasing by 78% to $17.1 million in Q2 2026.
• Transition from a net loss in Q2 2025 to a net income of $2.0 million in Q2 2026.
• Substantial improvement in Adjusted EBITDA, turning a loss of $1.2 million in Q2 2025 to a positive $2.8 million in Q2 2026.
• Increased cash and cash equivalents to $41.2 million, indicating a healthy liquidity position.
• Expansion of selling and marketing expenses, which appears to be driving sales growth, particularly with the AYA population.
• Positive results from investigator-initiated studies presented at ASCO 2026, reinforcing PEDMARK's utility and integration into patient care.
• Successful conclusion of patent litigation with Cipla, providing long-term exclusivity visibility for PEDMARK in the U.S. until September 1, 2033.

Negatives

• Selling and marketing expenses increased significantly to $10.7 million in Q2 2026 from $4.8 million in Q2 2025, impacting profitability margins despite revenue growth.
• While revenue is growing, the cost of product sales and selling/marketing expenses represent a substantial portion of revenue, indicating ongoing investment for growth.
• The company continues to have an accumulated deficit of $227.2 million.

Risks

• The company's ability to obtain additional financial resources may be necessary depending on future capital requirements.
• The success of PEDMARK relies on continued market penetration and acceptance, and competition from potential generic alternatives in the future.
• The company's projections of future capital requirements are subject to substantial uncertainty.
• There is a risk that the company may infringe on patents held by third parties or that third parties may claim infringement.
• The company's reliance on a limited number of distributors for PEDMARK sales in the U.S. could pose a concentration risk.
• The company's drug substance requirements to support clinical programs and commercialization activities could fluctuate.
• Changes in regulatory requirements or the outcome of regulatory reviews could impact the business.

Future Outlook

The company believes its existing cash and cash equivalents, together with expected revenues from operations, will be sufficient to fund its operating plan for at least the next twelve months. Projections of further capital requirements are subject to substantial uncertainty.

Management Comments

• Our second quarter reflects another period of strong execution across the business, highlighted by our seventh consecutive quarter of growth.
• We continue to build momentum by investing in the evidence that will shape the future of PEDMARK (sodium thiosulfate), with important data presented at ASCO and a growing pipeline of investigator-sponsored studies that we believe will further expand our understanding of its potential.
• As evidenced in our record EBITDA generation in the second quarter, we have a highly effective business model that is primed to optimize our anticipated growth while advancing our mission to improve outcomes for patients.

Industry Context

StockSavvy.ai notes that Fennec Pharmaceuticals operates in the specialty pharmaceutical sector, focusing on a niche but critical area of cancer treatment support. The strong growth in PEDMARK sales reflects increasing awareness and adoption of therapies aimed at mitigating severe side effects of chemotherapy, a growing concern in oncology.

Comparison to Industry Standards

• Fennec's revenue growth of 78% year-over-year in Q2 2026 for PEDMARK sales is a strong indicator of market penetration, especially for a specialty drug addressing a specific unmet need.
• The transition to profitability and positive Adjusted EBITDA demonstrates effective cost management and scaling of operations, which is a key benchmark for commercial-stage biopharmaceutical companies.
• The significant increase in selling and marketing expenses, while a drag on immediate profit, is a common strategy in the pharmaceutical industry to drive market adoption and establish a drug as a standard of care, as Fennec aims to do with PEDMARK.
• The company's focus on investigator-initiated studies and data presentation at major conferences like ASCO aligns with industry best practices for expanding the clinical utility and market reach of a drug.

Legal Proceedings

• The company is not currently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on its business, financial condition or results of operations.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability, and increased cash position, suggesting potential for future value appreciation.
• Patients: Continued access to PEDMARK, a critical therapy for reducing ototoxicity associated with cisplatin chemotherapy, with ongoing efforts to expand its use and understanding.
• Healthcare Providers: Increased support and education through expanded sales force and medical affairs teams, facilitating the integration of PEDMARK into patient care.
• Distributors: Continued partnership in distributing PEDMARK, with increased sales volume contributing to their business.

Next Steps

• Continue to increase market penetration and access for PEDMARK.
• Expand focus to the adolescent and young adult (AYA) population.
• Pursue regulatory registration strategy for PEDMARK in Japan.
• Evaluate partnering or licensing opportunities in Japan.
• Initiate additional investigator-sponsored studies to expand clinical evidence base for PEDMARK.
• Continue to present data at medical conferences to expand understanding of PEDMARK's clinical utility.
• Present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2026.

Key Dates

Recommendation

The company shows strong operational execution and revenue growth, with a clear path to profitability. However, the significant increase in operating expenses to fuel this growth, coupled with the ongoing need for capital and the inherent risks in the pharmaceutical industry, warrant a 'hold' recommendation pending sustained profitability and further de-risking of the business model.

Keywords

PEDMARK, Ototoxicity, Cisplatin, Pediatric Oncology, Adolescent and Young Adult Oncology, Pharmaceuticals, Drug Sales, Financial Results